Latest News

Delix in the news

Stay up to date with the latest Delix-related headlines.

nov 2023

What If Psychedelics’ Hallucinations Are Just a Side Effect?

View Article

july 2023

Recognizing inspiring achievements from 2023

View Article

sept 2022

Taking the tripping out of psychedelic medicine

View Article

sept 2022

Ketamine, psilocybin and ecstasy are coming to the medicine cabinet

View Article

Recent press releases

Dec 2023

Delix Therapeutics Awarded National Institutes of Health Grant to Advance Vital Research of Novel Neuroplastogen for Substance Use Disorders

View Article

Dec 2023

Delix Presents Interim Data From Phase I Trial of Novel Neuroplastogen at ACNP Annual Meeting

View Article

july 2023

The Galien Foundation Announces 2023 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup"

View Article

june 2023

Delix Therapeutics Announces Completion of 1st Cohort Dosing, Dose Escalation Approval in Phase I Trial for Novel Compound DLX-001

View Article

may 2023

Delix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001

View Article

june 2023

Delix Therapeutics Appoints Aaron Koenig, MD as Chief Medical Officer

View Article

feb 2023

Pioneering Delix Therapeutics Study Published in 'Science' Elucidates the Mechanism of Psychedelic-Induced Neuroplasticity

View Article

feb 2023

Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability

View Article

september 2022

Nature Biotechnology’s academic spinouts 2021

View Article

september 2022

Nature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up

View Article

september 2022

Delix Therapeutics Expands World-Class Team with First Head of R&D

View Article

september 2022

Delix Therapeutics and Pfizer UK Recognized as Gender Equity Champions for Women in the Workplace by Healthcare Businesswomen's Association

View Article

august 2022

Get Ready for the Magic Mushroom Pill

View Article

july 2022

Accessibility Is Key for the Psychedelic Revolution

View Article

july 2022

Taking the Magic Out of Magic Mushrooms

View Article

march 2022

Drug companies are investing big in psychedelics, but can they engineer out the trip?

View Article

january 2022

Delix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million Strategic Credit Facility Option in Partnership with Comerica Bank

View Article

january 2022

The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of

View Article

See what else we’ve been up to on LinkedIn.

Go to linkedin